Showing 2351-2360 of 2652 results for "".
- American Academy of Optometry Foundation Announces the 2020 Hopkins Comprehensive Eye Care Award Recipienthttps://modernod.com/news/american-academy-of-optometry-foundation-announces-the-2020-hopkins-comprehensive-eye-care-award-recipient/2478173/The American Academy of Optometry has announced that Charlotte Yiyi Wang, OD, is the recipient of this year’s recipient of the Hopkins Comprehensive Eye Care Award. Dr. Wang is a graduate of the University of California, Berkeley School of Optometry, and primary care/community health resident at
- Avellino Hits 1-Million Genetic Test Milestonehttps://modernod.com/news/avellino-hits-1-million-genetic-test-milestone/2478164/Avellino announced that the company has performed over 1-million genetic and molecular diagnostic tests. This milestone includes over 821,000 universal tests for TGFBI corneal dystrophy, over 180,000 AvellinoSARS-CoV-2/COVID-19 (AvellinoCoV2) tests since March 2020, and the November 2019 launch o
- Comparison of Mask Types Finds Key Differences in Filtrationhttps://modernod.com/news/comparison-of-mask-types-finds-key-differences-in-filtration/2478161/N95 masks that are well past their expiration date or have been used and re-sterilized are acceptable alternatives to standard new single-use N95 masks, new research indicates. But some masks start off with better filtration efficiency than others, according to a Medscape
- Multifocal Contact Lenses With High Add Power Help Slow Myopia Progressionhttps://modernod.com/news/multifocal-contact-lenses-with-high-add-power-help-slow-myopia-progression/2478162/Soft multifocal contact lenses with a high add power help slow progression of myopia in children, more so than multifocal lenses with medium add power or single-vision lenses, according to results of the BLINK trial, Reuters reported.
- Tom Frinzi Joins CorneaGen Board as Executive Chairhttps://modernod.com/news/tom-frinzi-joins-corneagen-board-as-executive-chair/2478159/CorneaGen announced that Tom Frinzi has joined the company’s board as executive chair. Mr. Frinzi brings more than 40 years of expertise in clinical-to-commercial transition and fostering next-level growth within small to mid-size private equity companies and Fortune 500 corporations. His
- Alcon Canada introduces PRECISION1 Contact Lenseshttps://modernod.com/news/alcon-canada-introduces-precision1-contact-lenses/2478144/Alcon has launched the PRECISION1 daily disposable, silicone hydrogel (SiHy) contact lenses in Canada. Designed to address the common issues that cause 1-in-5 new wearers to discontinue contact lens within the first year (poor vision, comfort and handling issues1), Precision1 he
- Regenxbio Announces Additional Positive Interim Phase 1/2a Trial Update for RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-additional-positive-interim-phase-1-2a-trial-update-for-rgx-314-for-the-treatment-of-wet-amd-2/2478113/Regenxbio reported positive 1 year data from patients in Cohorts 4 and 5 of the phase 1/2a trial of RGX-314 for the treatment of wet age-related macular degeneration (AMD). The company plans to initiate a pivotal program for subretinal delivery of RGX-314 in patients with wet AMD by the end of 20
- AAO: ACA’s Medicaid Expansion Failed to Improve Diabetic Dilated Eye Exam Rates Long-Termhttps://modernod.com/news/aao-acas-medicaid-expansion-failed-to-improve-diabetic-dilated-eye-exam-rates-long-term/2478111/New research shows significantly more people with diabetes got their critical annual dilated eye exam during the first 2 years following Medicaid expansion under the under the Affordable Care Act (ACA). However, this encouraging increase in the exam rate did not persist beyond 2 years. The study’
- MicroOptx Completes Patient Enrollment in Initial Phase of US Pivotal Trial for the Beacon Aqueous Microshunthttps://modernod.com/news/microoptx-completes-patient-enrollment-in-initial-phase-of-us-pivotal-trial-for-the-beacon-aqueous-microshunt/2478098/MicroOptx announced the completion of enrollment in the initial phase of the Beacon Study. This is the FDA investigational device exemption (IDE) clinical trial of the Beacon Aqueous Microshunt. Study participants treated during the initial phase of the interventional, single-arm, open label, mul
- TearLab Appoints Adam Szaronos as Chief Commercial Officerhttps://modernod.com/news/tearlab-appoints-adam-szaronos-as-chief-commercial-officer/2478094/TearLab announced the appointment of Adam Szaronos to the position of Chief Commercial Officer (CCO). Mr. Szaronos brings a wealth of experience gained over the past 15 years and will help guide the evolution of TearLab as it